Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Peter Schmid | Researchclopedia

Back to researchers

Peter Schmid

Queen Mary University of London

375

Works

24,308

Citations

61

h-index

148

i10-index

Research Topics

Advanced Breast Cancer Therapies Cancer Immunotherapy and Biomarkers HER2/EGFR in Cancer Research

Affiliations

Brighton and Sussex Medical School2011–2015

AstraZeneca (United Kingdom)2019–2019

Champalimaud Foundation2019–2019

Roche (Switzerland)2019–2021

National Health Service2019–2019

Top Works

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid,Sylvia Adams,et al.

20184,270 citations

Cancer Treatment and Pharmacology

Breast Cancer Treatment Studies

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid,Javier Cortés,et al.

20202,951 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés,David W. Cescon,et al.

20201,746 citations

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Peter Schmid,Hope S. Rugo,et al.

20191,174 citations

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Javier Cortés,Hope S. Rugo,et al.

20221,006 citations

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Leisha A. Emens,Cristina Cruz,et al.

2018780 citations

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

Sylvia Adams,Sherene Loi,et al.

2018620 citations

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino,Byoung Chul Cho,et al.

2018570 citations

Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

Tiffany A. Traina,Kathy D. Miller,et al.

2018492 citations